Express Scripts' Miller says hepatitis C price war to save billions

January 22, 2015 5:42 PM

4 0

NEW YORK (Reuters) - Gilead Sciences Inc and AbbVie Inc are in a price war over their hepatitis C treatments that is driving costs lower and has changed the way drugmakers price new medicines, a top executive for pharmacy benefit manager Express Scripts said on Thursday.

Gilead's hepatitis C drug Harvoni, which can cure a majority of patients who take it, has a retail price of $94,500 and is now facing its first competition with AbbVie's Viekira Pak, which was priced about $10,000 lower, or at $83,319.

Also read: Ohio State attacker was angry about treatment of Muslims, official says

Read more

To category page

Loading...